Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Drug Resistance, Neoplasm
  • Prostatic Neoplasms
  • Salvage Therapy

abstract

  • Carboplatin/paclitaxel chemotherapy following docetaxel in metastatic CRPC is well tolerated with favorable PSA response rates and survival. This combination is a viable option after progression on docetaxel-based therapy.

publication date

  • November 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.urolonc.2009.12.023

PubMed ID

  • 20451413

Additional Document Info

start page

  • 676

end page

  • 81

volume

  • 29

number

  • 6